These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36185171)

  • 1. Erratum: Patient Perceptions of Switching to a Generic Dry Powder Inhaler - Increased Understanding Through Journey Mapping [Corrigendum].
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2381-2382. PubMed ID: 36185171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Perceptions of Switching to a Generic Dry Powder Inhaler - Increased Understanding Through Journey Mapping.
    Ray SE; Boudewyns V; Davis C; Tzeng JP; Srivastava I; Oguntimein O; Conti DS; Feibus KB
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1751-1768. PubMed ID: 35965841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: The Effects Of Single Inhaler Triple Therapy Vs Single Inhaler Dual Therapy Or Separate Triple Therapy For The Management Of Chronic Obstructive Pulmonary Disease: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials [Corrigendum].
    Int J Chron Obstruct Pulmon Dis; 2020; 15():155-156. PubMed ID: 32021154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum to: Recent advances in capsule-based dry powder inhaler technology.
    Lavorini F; Pistolesi M; Usmani OS
    Multidiscip Respir Med; 2017; 12():19. PubMed ID: 28652914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.
    Yun Kirby S; Zhu CQ; Kerwin EM; Stanford RH; Georges G
    COPD; 2016; 13(2):167-75. PubMed ID: 26516724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to the Dry-Powder Inhaler Easyhaler
    Lavorini F; Chudek J; Gálffy G; Pallarés-Sanmartin A; Pelkonen AS; Rytilä P; Syk J; Szilasi M; Tamási L; Xanthopoulos A; Haahtela T
    Pulm Ther; 2021 Dec; 7(2):409-427. PubMed ID: 34581994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Response and Cost-Savings Associated With Generic Fluticasone Propionate/Salmeterol Multidose, Dry-Powder Inhaler in Asthma Patients Managed in an Ambulatory Care Practice Setting.
    McCarthy P; Iliadis T; Zaiken K
    J Pharm Pract; 2022 Apr; 35(2):274-280. PubMed ID: 33161797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness.
    Tashkin DP; Koltun A; Wallace R
    Allergy Asthma Proc; 2021 Jan; 42(1):30-35. PubMed ID: 33353582
    [No Abstract]   [Full Text] [Related]  

  • 9. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler.
    Allan R; Canham K; Wallace R; Singh D; Ward J; Cooper A; Newcomb C
    J Aerosol Med Pulm Drug Deliv; 2021 Apr; 34(2):134-145. PubMed ID: 32865454
    [No Abstract]   [Full Text] [Related]  

  • 10. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
    Svedsater H; Dale P; Garrill K; Walker R; Woepse MW
    BMC Pulm Med; 2013 Dec; 13():72. PubMed ID: 24314123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of inhaler technique and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler in chronic obstructive pulmonary disease (COPD): data on real-life clinical practice in Turkey.
    Öztürk C; Kaya A; Bilgin C; Yücesoy L; İkidağ B; Demirel M; Başlılar Ş; Şaylan B; Senol T; Ağanoğlu S; Can G; Doğrul MI; Çam M; Erdoğan N; Batum Ö; Turan MO; Demir C; Torun Ş; Cirit M; Turan M; Keleşoğlu A; Yaşar S; Uzunay Ö; Melek K; Altıparmak O
    Tuberk Toraks; 2012; 60(4):301-13. PubMed ID: 23289459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from branded to generic inhaled medications: potential impact on asthma and COPD.
    Lavorini F; Ninane V; Haughney J; Bjermer L; Molimard M; Dekhuijzen RP
    Expert Opin Drug Deliv; 2013 Dec; 10(12):1597-602. PubMed ID: 24224777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Effectiveness of Written Dry Powder Inhaler Instructions and Health Literacy in Subjects Diagnosed With COPD.
    Alsomali HJ; Vines DL; Stein BD; Becker EA
    Respir Care; 2017 Feb; 62(2):172-178. PubMed ID: 28028187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do healthcare professionals think that dry powder inhalers can be used interchangeably?
    Price D
    Int J Clin Pract Suppl; 2005 Dec; (149):26-9. PubMed ID: 16280000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment.
    Hawken N; Torvinen S; Neine ME; Amri I; Toumi M; Aballéa S; Plich A; Roche N
    BMC Pulm Med; 2017 Jul; 17(1):99. PubMed ID: 28683805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Clinical Trial Comparing the ELLIPTA and HandiHaler Dry Powder Inhalers in Patients With COPD: Inhaler-Specific Attributes and Overall Patient Preference.
    Collison KA; Patel P; Preece AF; Stanford RH; Sharma RK; Feldman G
    COPD; 2018 Feb; 15(1):46-50. PubMed ID: 29227727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost saving of switching to equivalent inhalers and its effect on health outcomes.
    Bloom CI; Douglas I; Olney J; D'Ancona G; Smeeth L; Quint JK
    Thorax; 2019 Nov; 74(11):1078-1086. PubMed ID: 31383774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].
    Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
    Respir Med; 2017 Aug; 129():164. PubMed ID: 28732826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.